GAITHERSBURG, Md., March 25, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for Strategic Preparedness and Response (ASPR), part of the U. S. Department of Health and Human Services (HHS), for smallpox preparedness. ASPR exercised an option from its existing 10-year contract (75A50119C00037) for additional do ...

Core Viewpoint - Emergent BioSolutions Inc. has appointed John D. Fowler, Jr. to its board of directors, effective March 1, 2026, to support the company's ongoing transformation and strategic priorities [1][2]. Group 1: Appointment Details - John D. Fowler, Jr. brings over 30 years of leadership experience in healthcare and financial services [1][2]. - He will serve on the Audit and Finance Committee of the board [1]. - Dr. Zsolt Harsanyi, chairman of the board, emphasized the importance of Fowler's experience in driving long-term shareholder value during the company's turnaround [2]. Group 2: Background of John D. Fowler, Jr. - Fowler is currently the chair of the board of trustees of the University of Virginia Darden School Foundation [2]. - He has held senior leadership roles at Wells Fargo Securities, Deutsche Bank, JPMorgan, and Salomon Brothers [3]. - His previous positions include president of Large Scale Biology Corporation and managing partner of Baycrest Capital [3]. Group 3: Educational Background - Fowler earned a Juris Doctor degree from the University of Virginia School of Law, an MBA from the University of Virginia Darden School of Business, and a Bachelor of Arts in History from the University of Virginia [4]. Group 4: Company Mission - Emergent BioSolutions has been dedicated to protecting public health for over 25 years, providing solutions for health threats such as smallpox, Ebola, and opioid overdoses [5].

Core Insights - Emergent BioSolutions Inc. (EBS) experienced a significant decline of approximately 27% in its stock price on Friday, primarily attributed to factors beyond its 2025 results [1]. Company Overview - Emergent BioSolutions is involved in the biotechnology sector, focusing on drug development and therapeutic research [1]. - The company aims to innovate through unique mechanisms of action and first-in-class therapies, which could potentially reshape treatment paradigms [1]. Analyst Perspective - The analysis emphasizes the importance of combining scientific expertise with financial and market analysis to deliver technically sound and investment-driven research [1]. - The focus is on evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and potential market opportunities while balancing financial fundamentals and valuation [1].

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - Neurogene Inc. (NGNE) is up 34% at $26.42 [3] - Cardio Diagnostics Holdings, Inc. (CDIO) is up 20% at $6.29 [3] - Applied Optoelectronics, Inc. (AAOI) is up 19% at $64.00 [3] - Caris Life Sciences, Inc. (CAI) is up 19% at $22.93 [3] - Block, Inc. (XYZ) is up 18% at $64.59 [3] - MARA Holdings, Inc. (MARA) is up 16% at $9.84 [3] - NCR Atleos Corporation (NATL) is up 14% at $48.13 [3] - Birchtech Corp. (BCHT) is up 12% at $2.70 [3] - The RealReal, Inc. (REAL) is up 11% at $13.80 [3] - Candel Therapeutics, Inc. (CADL) is up 10% at $5.68 [3] Premarket Losers - Duolingo, Inc. (DUOL) is down 24% at $88.30 [4] - Xponential Fitness, Inc. (XPOF) is down 23% at $6.16 [4] - Emergent BioSolutions Inc. (EBS) is down 22% at $8.58 [4] - Flutter Entertainment plc (FLUT) is down 14% at $105.85 [4] - Ginkgo Bioworks Holdings, Inc. (DNA) is down 14% at $8.27 [4] - Willdan Group, Inc. (WLDN) is down 12% at $104.63 [4] - Duos Technologies Group, Inc. (DUOT) is down 12% at $7.67 [4] - CoreWeave, Inc. (CRWV) is down 11% at $85.96 [4] - Zscaler, Inc. (ZS) is down 9% at $152.22 [4] - Progyny, Inc. (PGNY) is down 8% at $20.40 [4]

Core Viewpoint - Emergent BioSolutions, Inc. is discussing its operational and financial results for Q4 and the full year of 2025 during the earnings conference call [2]. Group 1: Financial Performance - The earnings call will cover both operational and financial results for the fourth quarter and the entire year of 2025 [2]. - The company may discuss non-GAAP financial measures to provide greater transparency regarding its operating performance [4]. Group 2: Forward-Looking Statements - Emergent may make projections and forward-looking statements related to its business and future performance, which are based on current intentions and beliefs [3]. - Any forward-looking statement is only valid as of the date of the conference call, and the company does not commit to updating these statements unless required by law [3].

Financial Data and Key Metrics Changes - In 2025, adjusted EBITDA reached $205 million, a $22 million or 12% year-over-year increase, with gross margin expanding by 900 basis points [11][12] - Adjusted net income per share improved from a loss of $0.23 in 2024 to earnings of $1.53 in 2025, reflecting enhanced competitiveness [12][17] - Total revenues for 2025 were $743 million, despite a decline compared to 2024, which included $150 million of settlement and divested revenue [14][15] Business Line Data and Key Metrics Changes - The medical countermeasures (MCM) business maintained strong performance, with international sales representing 34% of total revenue [6][15] - Naloxone's performance was impacted by temporary market uncertainties, but the company continues to invest in brand strength and product extensions [13][16] - Other revenue aligned with expectations at $60 million, reflecting the absence of prior one-time items [16] Market Data and Key Metrics Changes - International deliveries were made to over 20 countries, with a new multi-year agreement with the Canadian government valued at CAD 140 million [7][24] - The U.S. government shutdown created uncertainty for public interest customers, affecting commercial segment revenues [12][13] - The opioid overdose death rates in the U.S. have shown a meaningful decline, reinforcing the importance of naloxone access [8][9] Company Strategy and Development Direction - The company aims to invest in revenue growth drivers across both MCM and naloxone segments, focusing on internal pipeline advancements and targeted acquisitions [5][6] - There is a strong commitment to biodefense preparedness, with rising U.S. government spending across major federal programs [24] - The company plans to selectively invest cash generated from profitable segments into organic growth and external partnerships [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute on core business and long-term growth initiatives while improving operational profitability [25][26] - The outlook for 2026 anticipates total revenues in the range of $720 million to $760 million, with adjusted EBITDA expected between $135 million and $155 million [20][21] - The company highlighted the importance of ongoing investments in naloxone and biodefense as critical to future success [23][24] Other Important Information - The company repurchased 3.11 million shares under its stock buyback program and announced a new $50 million authorization for further repurchases [19] - Total liquidity at the end of 2025 was $305 million, including $205 million in cash [16][17] - The company reduced net leverage to 1.9 times from 3.3 times in the prior year, demonstrating improved financial flexibility [17][18] Q&A Session Summary - No questions were raised during the Q&A session, and the call concluded with management expressing appreciation for attendance [27][28]

Financial Data and Key Metrics Changes - In 2025, adjusted EBITDA reached $205 million, a $22 million or 12% year-over-year increase, with gross margin expanding by 900 basis points [11][12] - Adjusted net income per share improved from a loss of $0.23 in 2024 to earnings of $1.53 in 2025, reflecting enhanced competitiveness [12][17] - Total revenues for 2025 were $743 million, despite a decline compared to 2024, which included $150 million of settlement and divested revenue [14][15] Business Line Data and Key Metrics Changes - The medical countermeasures (MCM) business maintained strong performance, with international sales representing 34% of total revenue [6][15] - Naloxone's performance was impacted by temporary market disruptions, but the company continues to invest in brand strength and product extensions [16][20] - Other revenue aligned with expectations at $60 million, reflecting the absence of prior one-time items [16] Market Data and Key Metrics Changes - International deliveries were made to over 20 countries, with a new multi-year agreement with Canada valued at CAD 140 million [7][24] - The U.S. government shutdown created uncertainty for public interest customers, affecting naloxone demand [10][13] - The opioid overdose death rates in the U.S. have shown a meaningful decline, attributed to increased access to naloxone [8][9] Company Strategy and Development Direction - The company aims to invest in revenue growth drivers across both MCM and naloxone segments, focusing on internal pipeline advancements and targeted acquisitions [6][25] - There is a strong commitment to biodefense preparedness, with rising U.S. government spending across major federal programs [24] - The company plans to selectively invest cash generated from profitable segments into organic growth and external partnerships [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute on core business and long-term growth initiatives while improving operational profitability [26] - The outlook for 2026 anticipates total revenues between $720 million and $760 million, with adjusted EBITDA expected between $135 million and $155 million [20][21] - The company highlighted the importance of ongoing investments in naloxone and biodefense as critical to future success [23][24] Other Important Information - The company repurchased 3.11 million shares under its stock buyback program and announced a new $50 million authorization for further repurchases [19] - Total liquidity at the end of 2025 was $305 million, including $205 million in cash [16][17] - Net leverage improved to 1.9x from 3.3x in the prior year, demonstrating enhanced cash-generating capabilities [17][18] Q&A Session Summary - No questions were raised during the Q&A session, and the call concluded with closing remarks from the CEO [27][28]

Financial Data and Key Metrics Changes - Adjusted EBITDA for 2025 was $205 million, a $22 million or 12% year-over-year increase [12] - Gross margin expanded by 900 basis points, and operating expenses decreased by $140 million compared to 2024 [12] - Adjusted net income per share improved from a loss of $0.23 in 2024 to earnings of $1.53 in 2025 [13] - Total revenues for 2025 were $743 million, reflecting steady performance despite a decline compared to 2024 [14][16] Business Line Data and Key Metrics Changes - The medical countermeasures (MCM) business maintained strong performance with international sales representing 34% of total revenue [6][16] - NARCAN's performance was impacted by softer demand due to the U.S. government shutdown, but the company remains optimistic about long-term growth potential [14][21] - Other revenue was $60 million, aligning with expectations and reflecting the absence of prior one-time items [17] Market Data and Key Metrics Changes - International deliveries were made to over 20 countries, with significant contracts secured, including a CAD 140 million agreement with the Canadian government [7] - The U.S. opioid overdose death rates have shown a meaningful decline, which the company attributes to increased access to naloxone [8][10] Company Strategy and Development Direction - The company aims to invest in revenue growth drivers across both the MCM and naloxone segments, focusing on internal pipeline advancements and targeted acquisitions [5] - There is a strong commitment to biodefense preparedness, with rising U.S. government spending across major federal programs [26] - The company plans to selectively invest cash generated from profitable segments into organic growth and external partnerships [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute on core business and long-term growth initiatives while improving operational profitability [26] - The initial 2026 outlook projects total revenues between $720 million and $760 million, with expectations for MCM revenue to be flat to slightly down [21] - The company anticipates a healthy start to 2026, with first-quarter revenue expected to be between $135 million and $155 million [22] Other Important Information - The company repurchased 3.11 million shares under its stock buyback program and announced a new $50 million authorization for additional repurchases [20] - Total liquidity at the end of 2025 was $305 million, including $205 million in cash [18] Q&A Session Summary - No questions were raised during the Q&A session, and the call concluded with management expressing appreciation for attendance [29][30]

Financial Performance and Contracts - As of December 31, 2025, the company has a portfolio of 11 products addressing global public health threats, generating substantial revenue[18] - In 2023, the company completed the sale of its travel health business for $80 million, achieving all development milestones under the Purchase and Sale Agreement with Bavarian Nordic[23] - The company secured multiple contract actions in 2025, including $56 million for ACAM2000 and $62.4 million for BAT, supporting near- and mid-term deliveries[30] - The company announced approximately $27 million in incremental sales to international customers for five critical MCM products in 2025[30] - The company secured multiple government contracts in 2025, including ACAM2000 for $56 million, CYFENDUS for $30 million, and BAT for $62.4 million, totaling over $200 million in contract actions[30] - The ACAM2000 vaccine contract with the U.S. government is valued at up to approximately $2.0 billion over 10 years, with option exercises valued at $176.0 million and $182.2 million in 2020 and 2021 respectively[34] - The BAT antitoxin contract with HHS is valued at up to $550.0 million, with the first deliverable valued at approximately $90.0 million for annual doses over 10 years[34] - Ebanga (ansuvimab-zykl) has a 10-year contract with BARDA valued at up to $704 million for advanced development and procurement, with option exercises valued at approximately $41.9 million and $16.7 million in 2024 and 2025 respectively[35] - TEMBEXA, the first oral antiviral approved by the FDA for smallpox, has a 10-year contract with BARDA valued at up to $680 million, with additional procurement options worth approximately $67.4 million executed in 2024[37] Product Development and Innovation - The company plans to continue executing its multi-year turnaround plan with a focus on disciplined execution and long-term sustainable growth[32] - The company expanded its naloxone portfolio by acquiring exclusive commercial rights to KLOXXADO in the U.S. and Canada[29] - The FDA approved a supplemental BLA for the Winnipeg facility to support drug product manufacturing for raxibacumab, enhancing the company's manufacturing capabilities[29] - The company maintained a leadership position with NARCAN Nasal Spray, supported by strong demand and continued innovation in customer solutions[32] - NARCAN Nasal Spray was approved as an OTC medication in March 2023, becoming the first 4 mg naloxone nasal spray available OTC in the U.S., with nationwide distribution starting in August 2023[39] - KLOXXADO, a prescription product for opioid overdose, was taken over by Emergent for sales and marketing in the U.S. and Canada in 2025, with an 8 mg dose initially approved[41] - CYFENDUS vaccine, approved in July 2023, is designed to provide post-exposure prophylaxis with a two-dose regimen, and has contract modifications with BARDA valued at approximately $80.0 million in 2024[35] - The company has delivered a total of three million doses of CYFENDUS under a contract with BARDA, with additional options for up to 50 million doses[35] Regulatory Compliance and Legal Matters - The company is subject to strict regulations as a US government contractor, including potential penalties and compliance audits[69] - The FDA's "Animal Rule" allows for product approval based on animal study data when human trials are unethical or unfeasible, with post-approval trials required in case of bioterrorism or pandemics[77] - The company must submit an Investigational New Drug application (IND) to the FDA before initiating clinical trials, which includes pre-clinical testing results and manufacturing information[78] - The FDA may impose conditions on marketing approval, including enhanced labeling and post-approval clinical trials, which could impact commercial success[85] - The FDA requires that each product lot of many biologics, including vaccines, undergo testing for purity, potency, identity, and sterility before distribution[97] - The FDA can impose various sanctions for non-compliance, including product recalls, fines, and withdrawal of marketing approvals[113] Market Competition and Challenges - NARCAN Nasal Spray and KLOXXADO face generic competition, with Teva and Padagis launching their versions in 2021 and 2023 respectively[64] - TEMBEXA is the first oral antiviral approved for smallpox treatment, facing competition from TPOXX, which is also procured by the US government[64] - Ebanga, approved for Zaire Ebolavirus infection, faces competition from Inmazeb, which is also procured by the US government[60] - ACAM2000 vaccine remains the primary smallpox vaccine stockpiled by the US government, facing competition from JYNNEOS and KM Biologics LC16m8 vaccines[60] - CYFENDUS and BioThrax are the only anthrax vaccines procured by the US government, with potential future competition from other developing candidates[60] - The company relies on single-source suppliers for critical raw materials, including Alhydrogel adjuvant and components of NARCAN Nasal Spray[66] Corporate Governance and Employee Engagement - The company authorized a stock repurchase program of up to $50 million through March 2026, demonstrating a focus on disciplined capital allocation[29] - The company completed a sustainability compliance roadmap in 2025, establishing priorities for sustainability reporting and compliance with emerging regulations[131] - The company introduced an "equity for all" award in 2025, providing equity grants to employees not typically eligible for such awards[129] - The company’s total rewards plan includes comprehensive benefits, salaries, bonuses, and equity awards, emphasizing employee engagement and development[129] - As of December 31, 2025, the company had approximately 900 employees globally, maintaining a consistent workforce throughout the year[127] Strategic Partnerships and Future Outlook - The company engaged in strategic partnerships and targeted innovation to align with preparedness needs and capabilities[32] - The company decided to deprioritize several product candidates, including EBS-LASV and Pan-Ebola mAbs, at the end of 2025[43][46] - Emergent's bioservices include development and manufacturing services, supporting "molecule-to-market" solutions for biopharmaceutical companies and NGOs[49] - The company operates four development and manufacturing sites in the U.S. and Canada, meeting both internal and external manufacturing needs[50]

Our Mission: Protect and Save Lives February 26, 2026 1 Safe Harbor Statement/Trademarks This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements, other than statements of historical fact, including statements regarding the future performance of the Company or any of our businesses, our business strategy, future operations, future financial position, future revenues and earnings, our ability to achieve the ob ...